Literatur
-
1
Abrahamsson B, Lücker P, Olofsson B. et al .
The relationship between metoprolol plasma concentration and beta 1-blockade in healthy subjects: a study on conventional metoprolol and metoprolol CR/ZOK formulations.
J Clin Pharmacol.
1990;
30
S46-S54
-
2 BERLIN-CHEMIE AG .Fachinformation Nebilet®;. 2003
-
3
Cheymol G, Woestenborghs R, Snoeck E. et al .
Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects.
Eur J Clin Pharmacol.
1997;
51
493-498
-
4
Clark D W, Morgan A K, Waal-Manning H.
Adverse effects from metoprolol are not generally associated with oxidation status.
Br J Clin Pharmacol.
1984;
18
965-967
-
5
Collette D, Thürmann P A.
Unerwünschte Arzneimittelwirkungen. Erbliche Unterschiede im Arzneistoffmetabolismus.
Dtsch Med Wochenschr.
2002;
127
1025-1028
-
6
Dahl M L, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F.
Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
J Pharmacol Exp Ther.
1995;
274
516-520
-
7
Deroubaix X, Lins R L, Lens S. et al .
Comparative bioavailability of a metoprolol controlled release formulation and a bisoprolol normal release tablet after single oral dose administration in healthy volunteers.
Int J Clin Pharmacol Ther.
1996;
34
61-70
-
8
Eichelbaum M, Burk O.
CYP3A genetics in drug metabolism.
Nat Med.
2001;
7
285-287
-
9
Eichelbaum M, Spannbrucker N, Steincke B, Dengler H J.
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.
Eur J Clin Pharmacol.
1979;
16
183-187
-
10
Evans W E, McLeod H L.
Pharmacogenomics - drug disposition, drug targets, and side effects.
N Engl J Med.
2003;
348
538-549
-
11
Gottlieb S S, Fisher M L, Kjekshus J. et al .
Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF).
Circulation.
2002;
105
1182-1188
-
12
Graff D W, Williamson K M, Pieper J A. et al .
Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients.
J Clin Pharmacol.
2001;
41
97-106
-
13
Griese E U, Zanger U M, Brudermanns U. et al .
Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.
Pharmacogenetics.
1998;
8
15-26
-
14
Horikiri Y, Suzuki T, Mizobe M.
Stereoselective metabolism of bisoprolol enantiomers in dogs and humans.
Life Sci.
1998;
63
1097-1108
-
15 Human Allele Nomenclature Committee .Home Page of the Human Cytochrome P450 (CYP). http://www.imm.ki.se/CYPalleles/ 2004
-
16
Ingelman-Sundberg M.
Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms.
Naunyn Schmiedebergs Arch Pharmacol.
2004;
369
89-104
-
17
Keating G M, Jarvis B.
Carvedilol: a review of its use in chronic heart failure.
Drugs.
2003;
63
1697-1741
-
18
Komajda M, Follath F, Swedberg K. et al .
The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment.
Eur Heart J.
2003;
24
464-474
-
19
Lacourciere Y, Poirier L, Lefebvre J, Archambault F, Cleroux J.
Comparative assessment of antihypertensive efficacy of DL-nebivolol and D-nebivolol in patients with confirmed mild to moderate hypertension.
J Cardiovasc Pharmacol.
1995;
25
619-624
-
20
Lamba J K, Lin Y S, Schuetz E G, Thummel K E.
Genetic contribution to variable human CYP3A-mediated metabolism.
Adv Drug Deliv Rev.
2002;
54
1271-1294
-
21
Leineweber K, Büscher R, Bruck H, Brodde O E.
beta-Adrenoceptor polymorphisms.
Naunyn Schmiedebergs Arch Pharmacol.
2004;
369
1-22
-
22 Lemmer B. Betarezeptorenblocker. Berlin Heidelberg: Springer-Verlag In: Schwabe U, Paffrath D, editors. Arzneiverordnungsreport 2001 2001: 287-296
-
23
Lennard M S, Silas J H, Freestone S, Ramsay L E, Tucker G T, Woods H F.
Oxidation phenotype - a major determinant of metoprolol metabolism and response.
N Engl J Med.
1982;
307
1558-1560
-
24
Lennard M S, Tucker G T, Silas J H, Woods H F.
Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol.
Xenobiotica.
1986;
16
435-447
-
25
Leopold G.
Balanced pharmacokinetics and metabolism of bisoprolol.
J Cardiovasc Pharmacol.
1986;
8
S16-20
-
26
Lohse M J, Engelhardt S, Eschenhagen T.
What is the role of beta-adrenergic signaling in heart failure?.
Circ Res.
2003;
93
896-906
-
27
Mahgoub A, Idle J R, Dring L G, Lancaster R, Smith R L.
Polymorphic hydroxylation of Debrisoquine in man.
Lancet.
1977;
2
584-586
-
28
McNeely W, Goa K L.
Nebivolol in the management of essential hypertension: a review.
Drugs.
1999;
57
633-651
-
29
Meyer U A.
Pharmacogenetics and adverse drug reactions.
Lancet.
2000;
356
1667-1671
-
30
Raimundo S, Fischer J, Eichelbaum M, Griese E U, Schwab M, Zanger U M.
Elucidation of the genetic basis of the common ‘intermediate metabolizer’ phenotype for drug oxidation by CYP2D6.
Pharmacogenetics.
2000;
10
577-581
-
31
Rau T, Heide R, Bergmann K. et al .
Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment.
Pharmacogenetics.
2002;
12
465-472
-
32
Roden D M.
Cardiovascular pharmacogenomics.
Circulation.
2003;
108
3071-3074
-
33
Sachse C, Brockmöller J, Bauer S, Roots I.
Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.
Am J Hum Genet.
1997;
60
284-295
-
34
Siddoway L A, Thompson K A, McAllister C B. et al .
Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.
Circulation.
1987;
75
785-791
-
35
Van Rooy P, De Crée J.
Haemodynamic effects of nebivolol in poor and extensive metabolisers.
Drug Investig.
1991;
3
161-163
-
36
Wadworth A N, Murdoch D, Brogden R N.
Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.
Drugs.
1991;
42
468-510
-
37
Wagner F, Kalusche D, Trenk D, Jähnchen E, Roskamm H.
Drug interaction between propafenone and metoprolol.
Br J Clin Pharmacol.
1987;
24
213-220
-
38
Wuttke H, Rau T, Heide R. et al .
Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.
Clin Pharmacol Ther.
2002;
72
429-437
-
39
Zanger U M, Raimundo S, Eichelbaum M.
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Naunyn Schmiedebergs Arch Pharmacol.
2004;
369
23-37
-
40
Zhou H H, Wood A J.
Stereoselective disposition of carvedilol is determined by CYP2D6.
Clin Pharmacol Ther.
1995;
57
518-524
Prof. Dr. med. Thomas Eschenhagen
Institut für Experimentelle und Klinische Pharmakologie, Universitätsklinikum Hamburg-Eppendorf
Martinistraße 52
20246 Hamburg
Phone: +49/40/428033180
Fax: +49/40/428034876
Email: t.eschenhagen@uke.uni-hamburg.de
